An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...

Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS-mutated mCRC. Cardiff Oncology plans a registrational trial to compare ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human ...

Cardiff Oncology saw its shares nosedive following the departure of its CEO and CFO, plus questions about some Phase II data for its candidate onvansertib in first-line RAS-mutated metastatic ...

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...

Highlights: The study examines anti-RAS activity in a series of RAS inhibitors with a predicted unique interaction region. The compounds, in development at Qualigen Therapeutics, bind wild type KRAS ...